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Purpose: To evaluate the kinetics of serum testosterone (T) recovery following 
short-term androgen deprivation therapy (ADT), as the understanding thereof is 
essential for the proper management of prostate cancer (PCa), especially intermit-
tent ADT. Materials and Methods: This prospective analysis included male sex 
offenders who voluntarily received leuprolide acetate in order to alleviate sexual 
aberrance. Thirty-three and 25 patients who received 3 and 6 months of ADT were 
assigned to Group A and Group B, respectively. Serum T levels were obtained ev-
ery week during the on-cycle period, then monthly during the off-cycle period for 
at least 12 months. Results: The kinetics of serum T during the on-cycle period 
were similar in both groups. After flare reaction at week 2, a nadir of 0.45±0.29 
ng/mL was achieved. In Group A, an abrupt rebound-upsurge was observed during 
the first 2 month off-cycle period, which surpassed the baseline level and reached 
a plateau level of 8.74±2.11 ng/mL during the flare (p<0.001). This upsurge was 
followed by a gradual decline back to baseline over the following 10 months. In 
Group B, a gradual increase was observed, and a baseline level of 7.26±1.73 ng/
mL was reached at 5 months. Thereafter, an ongoing upsurge that surpassed base-
line levels was observed until 12 months (8.81±1.92 ng/mL; p=0.002). Conclu-
sion: The kinetics of serum T recovery during the off-cycle period varied accord-
ing to the duration of ADT. Serum T should be monitored beyond normalization, 
as an excessive rebound may improve quality-of-life, but hamper the treatment ef-
ficacy of PCa.
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INTRODUCTION
Androgen-deprivation therapy (ADT) is the mainstay of initial treatment of andro-
gen-sensitive, metastatic, or advanced stage prostate cancer (PCa).1 However, 
long-term ADT is associated with adverse effects such as hot flashes, decreased li-
bido, loss of bone mineral density, depressive mood, and cognitive dysfunction, 
most of which are the results of deficient serum testosterone (T).2 To alleviate 
these unwanted effects for patients who are unable to accept such potential risks, 
Original Article http://dx.doi.org/10.3349/ymj.2014.55.3.570pISSN: 0513-5796, eISSN: 1976-2437          Yonsei Med J 55(3):570-575, 2014
Testosterone Recovery after Androgen Ablation
Yonsei Med J   http://www.eymj.org   Volume 55   Number 3   May 2014 571
cessive sexual aberrancy. Participation was completely vol-
untary and not a condition of parole or probation. Written 
informed consent was obtained from all patients with ap-
proval by the institutional ethics committee (1-219577-AB-
N-01-201306-HR-008).
Laboratory tests, namely complete blood cell count, serum 
chemistry, PSA, and sex hormones, including T, luteinizing 
hormone (LH), and follicle-stimulating hormone (FSH), for 
all patients were within accepted normal ranges (T: 2.65- 
8.0 ng/mL, LH: 1.8-8.6 mIU/L, and FSH: 1.5-12.4 mIU/
mL). Serum T, LH, and FSH were measured using a mic-
roparticle enzyme immunoassay (Abbott® laboratories, Chi-
cago, IL, USA). All patients were ADT-naïve without con-
traindications to receiving ADT, such as, allergy against the 
drug, osteoporosis, history of thromboembolism, liver fail-
ure, or pituitary pathology.12 A one-month formulation of 
leuprolide acetate (LA) 3.75 mg was injected subcutane-
ously every month. Thirty three and 25 patients chose to 
discontinue ADT after 3 and 6 months, and were allocated 
as Group A and Group B, respectively. With all test results 
blinded, the decision for ADT cessation was based on the 
severity of adverse effects or done at the patient’s insistence 
on discontinuation. Measurements of mid-morning serum 
T, LH, and FSH were obtained every week during the on-
cycle period, then monthly during the observational off-cy-
cle period of at least 12 months. The castrate level of serum 
T was defined as less than 0.7 ng/mL.13
Statistical analysis was performed using SPSS software, 
version 18, for Windows (SPSS Inc., Chicago, IL, USA). 
Descriptive statistics were used to analyze the frequency of 
events; the Mann-Whitney U test was used to compare dif-
ferences between groups; and the χ2-test was used for the 
analysis of two or more variables. Mean values and stan-
dard deviations for serum T, LH, and FSH were calculated.
 
RESULTS
 
The demographic characteristics of Group A and Group B 
are shown in Table 1. The mean age of both groups was 35.7 
years (range 21-56). The kinetics of serum T during the on-
cycle period were similar in both groups, achieving a mean 
nadir of 0.45±0.29 ng/mL from the baseline level of 5.28± 
1.43 ng/mL. Flares were observed at 2 weeks, with serum T 
levels reaching up to 9.71±2.34 ng/mL. Trends in serum T 
values for each group are presented in Table 2.
Distinct patterns of serum T recovery between the two 
intermittent ADT (IADT) is an alternative. A number of 
randomized clinical trials have observed IADT to reduce 
side effects and costs, with comparable oncological out-
comes to ADT.3 Although its long-term efficacy remains un-
determined, the current National Comprehensive Cancer 
Network guidelines suggest IADT to confer better patient 
tolerability without altering overall survival, compared to 
continuous ADT.4
Understanding the kinetics of serum T during the IADT 
off-cycle period is essential when deciding upon the timing 
and the duration of on- and off-cycles. Studies of the trends 
of serum T normalization during the off-cycle have report-
ed highly variable results according to ADT duration, pa-
tient age, baseline serum T levels, or previous treatments 
for PCa [e.g. radical prostatectomy or external beam radia-
tion therapy (EBRT)].1,5-7 However, surveys have demon-
strated that only a minority of clinicians regularly monitor 
serum T, and instead base the decision to resume therapy 
following the off-cycle of prostate-specific antigen (PSA) 
levels.8 Certainly, understanding the kinetics of serum T re-
covery according to ADT duration is essential, as PSA is a 
tissue-specific protein that is strongly androgen dependent 
and the growth of PCa cells and progression to metastatic 
disease is dependent on serum T.9 Moreover, serum T above 
castrated levels following ADT is a reflection of insufficient 
suppression of androgens, and thus, could serve as an indi-
cator for resuming therapy.10
A broad range of indications for ADT other than PCa in-
cludes precocious puberty, ovarian hyperandrogenism, and 
aberrant sexual behavior. We have previously reported treat-
ment outcomes in a group of sex offenders who received 
ADT in an attempt to alleviate excessive sexual drive.11 
Herein, implications for ADT schedule in regard to the ob-
served patterns of serum T recovery will be newly discussed 
from a perspective of PCa. To the best of our knowledge, 
our observation was the first to investigate the kinetics of se-
rum T recovery on a monthly basis following short-term 
ADT in a treatment-naïve, non-cancerous cohort.
MATERIALS AND METHODS
　　　
This prospective analysis included sex offenders incarcerat-
ed in the National Forensic Hospital who received chemical 
castration from 2011 to 2013. After a detailed explanation 
of the therapeutic effects and possible risks, 58 patients vol-
unteered to receive ADT in an attempt to self-alleviate ex-
Kyo Chul Koo, et al.
Yonsei Med J   http://www.eymj.org   Volume 55   Number 3   May 2014572
DISCUSSION
IADT is an accepted option among multidisciplinary treat-
ments for metastatic or advanced stage PCa, offering a few 
potential advantages, such as improved sexual function, de-
creased risk of ADT-related adverse events, and reduced 
medical cost.14 There is accumulating evidence that pre-
serving the hormone-dependent state of a tumor for an ex-
tended period may possibly alter progressive, metastatic 
disease into a chronic state that is amenable to long-term 
control.15 A key issue in IADT is that serum T levels should 
actually recover during the off-cycle in order to alleviate the 
adverse effects related to castrated levels of T, but at the same 
time, should not become high enough to stimulate the prolif-
eration of existing PCa cells or exacerbate tumor flares.16 It is 
surprising that the majority of clinicians assess treatment 
groups were noted during the off-cycle period. In Group A, 
an abrupt rebound-upsurge was observed during the first 2 
months. This rebound surpassed the baseline level of 4.97± 
1.21 ng/mL, and almost reached a plateau level of 8.74±2.11 
ng/mL, which was observed during the flare (p<0.001). A 
subsequent gradual decrease was observed over 10 months 
before serum T reached its baseline levels (Table 2, Fig. 1). 
In Group B, a slow gradual increase in serum T level was 
observed throughout the off-cycle period, and a baseline lev-
el of 7.26±1.73 ng/mL was achieved at 5 months. The re-
bound-surge phenomenon seen in Group A was not evident 
in Group B. However, following normalization at 5 months, 
an ongoing upsurge was observed until the last off-cycle 
follow-up at 12 months (8.81±1.92 ng/mL), which signifi-
cantly surpassed the mean baseline level (p=0.002) (Table 
2, Fig. 2). Trends in serum T recovery corresponded to al-
teration of serum LH levels in all groups.
Table 1. Demographic Characteristics of Patients Who Had Received 3 Months (Group A) and 6 Months (Group B) of ADT
Group A (n=33) Group B (n=25)
Age (yrs), baseline   36.6 (9.33) 34.9 (7.3)
BMI (kg/m2), baseline 23.9 (1.1) 23.5 (1.7)
PSA (ng/mL), baseline     1.1 (0.15) 0.91 (0.1)
Achievement of castrated levels of  T following ADT*          30 (90.1%)       22 (88%)
Achievement of normalization of  T following ADT         33 (100%)         25 (100%)
ADT, androgen deprivation therapy; BMI, body mass index; PSA, prostate-specific antigen; T, testosterone.
Data are mean (SD) and number (%).
*Castrated levels of serum T defined as <0.7 ng/mL.
Table 2. Kinetics of Mean Serum Testosterone, Luteinizing Hormone, and Follicle-Stimulating Hormone of Patients Who Had 
Received 3 Months (Group A) and 6 Months (Group B) of ADT
Group A (n=33) Group B (n=25)
T (ng/mL) LH (mIU/mL) FSH (mIU/mL) T (ng/mL) LH (mIU/mL) FSH (mIU/mL)
Baseline 4.97 (1.21) 2.83 (1.45) 3.25 (2.15)   5.71 (1.73) 2.11 (0.81) 3.14 (1.96)
On-cycle period
    Flare plateau 8.74 (2.11) 6.14 (2.95) 4.25 (2.78) 12.08 (2.65) 7.58 (3.12) 6.12 (2.48)
    Nadir 0.24 (0.21) 0.25 (0.18) 2.28 (1.14)   0.64 (0.47) 0.14 (0.09) 1.12 (0.91)
Off-cycle period
    1 month 6.85 (2.65) 5.15 (1.75) 3.25 (2.15)   1.51 (1.22) 0.52 (0.34) 1.56 (0.89)
    2 months 8.01 (1.87) 6.13 (1.98) 2.83 (1.49)   1.63 (0.97) 1.24 (0.74) 1.65 (1.13)
    3 months 7.03 (1.95) 3.96 (0.11) 2.57 (1.48)   3.81 (2.17) 2.07 (0.98) 1.01 (1.03)
    4 months 6.38 (2.46) 2.77 (1.58) 2.32 (1.54)   4.47 (1.02) 2.17 (1.12) 1.26 (1.22)
    5 months 6.34 (1.25) 4.22 (1.32) 3.54 (2.19)   7.26 (1.73) 4.32 (2.47) 2.04 (1.47)
    6 months 6.01 (2.73) 2.14 (1.18) 2.89 (1.87)   8.73 (2.25) 5.27 (2.46) 4.34 (2.83)
    7 months 6.43 (1.97) 3.72 (2.14) 3.31 (2.18)   8.66 (1.74) 5.82 (2.91) 4.25 (1.87)
    9 months 5.81 (1.89) 1.36 (1.11) 3.37 (2.32)   7.95 (1.68) 3.90 (1.91) 4.11 (2.22)
    10 months 5.09 (2.57) 2.79 (1.95) 3.21 (2.08)   9.23 (2.17) 5.35 (3.51) 4.83 (2.14)
    12 months 5.31 (1.21) 2.32 (1.45) 3.24 (2.11)   8.81 (1.92) 5.82 (2.49) 4.35 (2.39)
    14 months 5.68 (2.91) 2.22 (1.32) 2.87 (1.19)
T, testosterone; LH, luteinizing hormone; FSH, follicle-stimulating hormone; ADT, androgen deprivation therapy.
Data are mean (SD).
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long-term ADT of more than 4 years, 53% of subjects were 
reported to remain castrated after 2.5 years.14 Common limi-
tations of previous publications included long intervals be-
tween serum T measurements in which time to normalization 
may have been overestimated, the inclusion of patients re-
ceiving concurrent treatment for PCa such as EBRT, and 
endpoints that focused on time to serum T normalization 
with no further follow-up thereafter. Our observation was 
the first to monitor long-term trends in serum T recovery 
after 3 and 6 months of short-term ADT on a monthly ba-
sis, and discerned that at least a 6-month on-cycle period is 
required for stable normalization of serum T in IADT.
The biology of serum T recovery following administra-
tion of LA is unknown. LA initially stimulates gonadotro-
pin-releasing hormone (GnRH) receptors in the pituitary 
gland, the so-called the ‘flare phenomenon’, but eventually 
causes desensitization and downregulation of GnRH recep-
tors, resulting in decreased secretion of LH and FSH. This 
response during IADT without monitoring serum T, consid-
ering that serum T above castrated levels is a reflection of 
insufficient suppression of androgens, and thus, could serve 
as an indicator for resuming ADT.
The kinetics of serum T recovery after cessation of ADT 
vary highly according to treatment settings.7,15 Studies on 
the recovery trends of serum T following 3 months of neo-
adjuvant ADT have reported that serum T remains at cas-
trate levels for 3 months following ADT cessation and grad-
ually achieves baseline levels at 7 months.7 However, a 
major confounder has been the inclusion of patients who re-
ceived EBRT during the observational period, which may 
have decreased testicular production of T.16 Hall, et al.17 ob-
served that castrate levels of serum T persist for up to 12 
months after discontinuing ADT of more than 2 years dura-
tion. The limitation of their study was that the included pa-
tients were on ADT at the time of enrollment, and thus base-
line serum T levels were unknown. In another study of 
Fig. 1. Trends of mean serum testosterone (ng/mL), luteinizing hormone (mIU/mL), and follicle-stimulating hormone (mIU/mL) recoveries during on- and off-
cycle periods of 3-month androgen deprivation therapy with leuprolide acetate. LH, luteinizing hormone; FSH, follicle-stimulating hormone; ADT, androgen 
deprivation therapy.
Fig. 2. Trends of mean serum testosterone (ng/mL), luteinizing hormone (mIU/mL), and follicle-stimulating hormone (mIU/mL) recoveries during on- and off-
cycle periods of 6-month androgen deprivation therapy with leuprolide acetate. LH, luteinizing hormone; FSH, follicle-stimulating hormone; ADT, androgen 
deprivation therapy.
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of GnRH agonists. Finally, there is a paucity of evidence 
relating excessively high levels of serum T to cancer pro-
gression. However, the results of the Prostate Cancer Pre-
vention Trial and the REDUCE study indicate that reduc-
tions in potent androgens by 5α-reductase inhibitors decrease 
the relative risk of PCa and indirectly link excessive serum 
T and PCa oncogenesis.20,21 Additional studies are needed 
to determine whether the current observation will have clin-
ical significance in the management of PCa patients on 
IADT.
The kinetics of serum T recovery during the IADT off-cy-
cle varies according to the treatment duration. Precautions 
should be taken when performing short-term ADT, because 
an excessive serum T surge during the off-cycle may im-
prove QoL, but hamper treatment efficacy. If confirmed, 
these preliminary data will have important implications for 
patient management and future clinical studies, including 
the discontinuation of GnRH agonists in the setting of neo-
adjuvant and adjuvant therapy, and especially in IADT.
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